Quiz: Role of Long Non-Coding RNAs in Ovarian Cancer

Article

How much do you know about the role of long non-coding RNAs in ovarian cancer? Now is your chance to find out.

In our September ovarian cancer quiz, you’ll be able to test your knowledge of the role long non-coding RNAs play in this disease. Here’s your first question:

1. In ovarian and other gynecologic cancers, long non-coding RNAs (lncRNAs) are key players in:

A. Cell proliferation

B. Invasion

C. Metastasis

D. All of the above


Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Related Content
The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Relacorilant/Chemo Show Survival Benefit in Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
April 2nd 2025
Article

The phase 3 ROSELLA trial results assessing relacorilant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROC

Megan Hollasch
March 17th 2025
Article

A phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer

Russ Conroy
March 17th 2025
Article

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.